Streetbeat News

Products Services

GOOGL

Google Cloud, a division of Alphabet Inc. (NASDAQ:GOOGL), has partnered with Web3Auth to launch a new Firebase extension for businesses to transition to Web3. This follows Google Cloud's recent collaboration with Polygon Network as a validator. The new extension will allow existing businesses and applications on Firebase to onboard their users onto Web3, integrating both frontend and backend capabilities. The offering is backed by Google Kubernetes Engine for autoscaling and Cloud Armor for network security.

Portfolio Pulse from Khyathi Dalal

October 02, 2023 | 1:03 pm

TSLA

Tesla Inc has announced its Q3 production and delivery numbers. The company produced over 430,000 vehicles and delivered over 435,000 vehicles. The Q3 deliveries included 419,074 units of Model 3/Y and 15,985 units of Model S/X. The production of Model 3/Y was 416,800 units.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2023 | 1:03 pm

NTRA

Natera, Inc. (NASDAQ:NTRA) has submitted the first module of its premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA) for Signatera, a personalized and tumor-informed molecular residual disease (MRD) test. The submission is part of a series of applications for multiple cancer types, starting with a companion diagnostic (CDx) assay for patients with muscle-invasive bladder cancer (MIBC). The remaining modules, including software, analytical and clinical validation data, are expected to be submitted through 2025.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2023 | 1:01 pm

NURO

NeuroMetrix (NURO) has announced a collaboration with the National Fibromyalgia Association to improve the quality of life for people living with fibromyalgia. The partnership aims to develop and promote better understanding and management of the condition.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2023 | 1:01 pm

NVS

Novartis AG has announced positive interim results from the Phase 3 APPLAUSE-IgAN study of iptacopan, a therapy for IgA nephropathy (IgAN), a rare kidney disease. The study showed iptacopan's superiority over placebo in reducing proteinuria. The safety profile was consistent with previous data. The study continues to evaluate iptacopan’s ability to slow IgAN progression. Novartis plans to submit for possible accelerated approval with the FDA in 2024. Novartis shares are down 0.30% at $101.55 during the premarket session.

Portfolio Pulse from Vandana Singh

October 02, 2023 | 12:59 pm

NVDA

A report from Tokyo's Akihabara Electric Town district indicates a shortage of Nvidia's GeForce RTX 40 series graphics cards, particularly the high-end RTX 4090. The shortage is attributed to a supply-demand imbalance, with some speculating that Nvidia may be prioritizing AI GPU customers. Retail back orders are longer for GPUs priced around $1,670. While some believe the shortage may be intentional to offload RTX 30 stocks, US retailers like Amazon and Newegg currently have ample stocks of GeForce RTX 4090 models.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2023 | 12:56 pm

MODG

Topgolf, a modern golf entertainment company, is set to open its first venue in Rhode Island and New England on October 6. The venue, which is Topgolf's 91st globally and 81st in the U.S., will employ around 500 people. The venue features 102 outdoor climate-controlled hitting bays, Toptracer technology, a full-service restaurant, and private event rooms. The opening is seen as a significant economic boost for the region, promising jobs and economic growth.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2023 | 12:50 pm

NIO

NIO Inc announced its delivery numbers over the weekend, with 15,641 vehicles delivered in September, a 43.8% YoY increase. Q3 deliveries totaled 55,432, up 75.4% YoY. The company also launched and began delivering its all-new coupe SUV EC6. Despite these positive numbers, NIO shares trended lower last month and were down 0.11% at the time of publication.

Portfolio Pulse from Adam Eckert

October 02, 2023 | 12:49 pm

SYRS

Syros Pharmaceuticals is planning a workforce reduction of approximately 35% to focus on the late-stage development of Tamibarotene in MDS and AML and ongoing pre-launch activities.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2023 | 12:49 pm

SYRS

Syros Pharmaceuticals (NASDAQ:SYRS) announced a strategic realignment and CEO transition. Conley Chee, CCO and CBO, will succeed Nancy Simonian as CEO, effective December 1, 2023. The company plans a workforce reduction of approximately 35% to focus on late-stage development of tamibarotene in MDS and AML. Syros will stop further investment in SY-2101 due to capital constraints. The company is preparing to report initial data from SELECT-AML-1 later this year and pivotal data from SELECT-MDS-1 next year.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2023 | 12:49 pm